行情

ATNM

ATNM

Actinium制药
AMEX

实时行情|Nasdaq Last Sale

0.2740
-0.0060
-2.14%
盘后: 0.2710 -0.003 -1.09% 17:49 01/17 EST
开盘
0.2780
昨收
0.2800
最高
0.2824
最低
0.2659
成交量
321.70万
成交额
--
52周最高
0.7085
52周最低
0.1900
市值
4,498.29万
市盈率(TTM)
-1.5471
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ATNM 新闻

  • Actinium up 11% on gene therapy collaboration
  • Seeking Alpha - Article.4天前
  • Actinium (ATNM) Upgraded to Strong Buy: Here's Why
  • Zacks.4天前
  • One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price
  • Simply Wall St..4天前
  • Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma
  • PR Newswire.4天前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ATNM 简况

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
展开

Webull提供Actinium Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。